On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...
Cryopyrin-associated periodic syndromes (CAPS) are a family of related conditions associated with heterozygous mutations in NLRP3 (formerly CIAS1), the gene that encodes the NACHT, LRR and PYD ...
Ilaris was approved by the FDA in 2009 to treat two subtypes of a rare autoinflammatory disease called Cryopyrin-Associated Periodic Syndromes (CAPS): Muckle-Wells syndrome (MWS) and Familial Cold ...
Insight 数据库显示,利纳西普早在 2008 年就获得美国 FDA 批准上市,商品名为 ARCALYST®,用于治疗 冷吡啉相关的周期性综合征 (CAPS),包括家族性寒冷型自身炎症综合征 (FCAS)和穆-韦二氏综合征 (MWS);2020 ...